---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-059570"
form_type: "8-K"
ticker: null
cik: "0001403708"
company_name: "Evoke Pharma Inc"
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:35:56.643099+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Evoke Pharma Q1 net product sales up 114% to $1.7M; reiterates $14M 2024 guidance

## Summary
- Net product sales of $1.7M vs $0.8M in Q1 2023; net loss of $1.6M ($0.17/share) improved from $2.2M ($0.67/share).
- Prescriber count grew 70% QoQ; medication fills increased 10% in Q1 2024 despite February cyberattack on claims processor.
- Raised $8.8M gross from public offering and warrant exercises; cash $9.7M expected to fund ops into Q1 2025.
- Reaffirmed full-year 2024 net revenue guidance of approximately $14M.
- Strengthened distribution partnership with ASPN Pharmacies and plans to present nasal metoclopramide data at DDW 2024.

## SEC filing metadata
- accession: 0000950170-24-059570
- form_type: 8-K
- cik: 0001403708
- company_name: Evoke Pharma Inc
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1403708/000095017024059570/0000950170-24-059570-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1403708/000095017024059570/evok-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-059570
- JSON: https://secwatch.observer/filing/0000950170-24-059570.json
- Plain text: https://secwatch.observer/filing/0000950170-24-059570.txt

## Key facts
- Earnings Releases
  Evoke Pharma Inc reported the first quarter ended March 31, 2024 results: revenue approximately $1.7 million, net income approximately $1.6 million, EPS $0.17 per share.
  - Period: the first quarter ended March 31, 2024
  - Revenue: approximately $1.7 million
  - Net income: approximately $1.6 million
  - EPS: $0.17 per share
  - Result: reported results
  source text: physicians and the positive experiences shared by patients underscore the growing demand and trust in GIMOTI.” “In the first quarter of 2024, our net revenue of approximately $1.7 million faced marginal impacts from transient challenges, including a cyberattack on the largest U.S. medical claims processor and an increase in co-pay expenses covered by Evoke. The
  evidence_url: https://www.sec.gov/Archives/edgar/data/1403708/000095017024059570/0000950170-24-059570-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.